The initiative, which will benefit Johns Hopkins and six other institutions, will be named in honor of Vivien Thomas, best known for his work treating “blue baby syndrome.”
As coronavirus infection rates decline, fewer are getting tested for the virus. The Biden administration wants to reverse that to ensure that schools and workplaces can reopen safely.
The vital medical devices could be inexpensive and available over the counter. But efforts have stalled under the F.D.A.
The university and its medical system have long celebrated their founding benefactor as a staunch abolitionist. But newly surfaced documents tell a different story.
There likely isn’t a robotics teacher institute in the world actively pursuing robotic learning. The field, after all, holds the key to unlocking a lot of potential for the industry. One of the things that makes it so remarkable is the myriad different approaches so many researchers are taking to unlock the secrets of helping robots essentially learn from scratch.
A new paper from Johns Hopkins University sporting the admittedly delightful name “Good Robot” explores the potential of learning through positive reinforcement. The title derives from an anecdote from author Andrew Hundt about teaching his dog to not chase after squirrels. I won’t go into that here — you can just watch this video instead:
But the core of the idea is to offer the robot some manner of incentive when it gets something correct, rather than a disincentive when it does something wrong. For robots, incentives come in the form of a scoring system — essentially a kind of gamification that rewards a number of points based on correctly executing a task.
The PhD candidate says the method was able to reduce the training time of a task significantly. “The robot wants the higher score,” Hundt said in a release tied to the research. “It quickly learns the right behavior to get the best reward. In fact, it used to take a month of practice for the robot to achieve 100% accuracy. We were able to do it in two days.”
The tasks are still quite elementary, including stacking bricks and navigating through a video game, but there’s hope that future robots will be able to work up to more complex and useful real-world tasks.
At its Ignite conference, Microsoft today announced that Premonition, a robotics and sensor platform for monitoring and sampling disease carriers like mosquitos and a cloud-based software stack for analyzing samples, will soon be in private preview.
The idea here, as Microsoft describes it, is to set up a system that can essentially function as a weather monitoring system, but for disease outbreaks. The company first demonstrated the project in 2015, but it has come quite a long way since.
Premonition sounds like a pretty wild project, but Microsoft says it’s based on five years of R&D in this area. The company says it is partnering with the National Science Foundation’s Convergence Accelerator Program and academic partners like Johns Hopkins University, Vanderbilt University, the University of Pittsburgh and the University of Washington’s Institute for Health Metrics and Evaluation to test the tools it’s developing here. In addition, it is also working with pharmaceutical giant Bayer to “develop a deeper understanding of vector-borne diseases and the role of autonomous sensor networks for biothreat detection.”
Currently, it seems, focus is on diseases transmitted by mosquitos and Microsoft actually set up a ‘Premonition Proving Ground’ on its Redmon campus to help researchers test their robots, train their machine learning models and analyze the data they collect. In this Arthropod Containment Level 2 facility, the company can raise and analyze mosquitos. But the idea is to go well beyond this and monitor the entire biome.
So far, Microsoft says, the Premonition system has scanned more than 80 trillion base-pairs of genomic material for biological threats.
“About five years ago, we saw that robotics, AI and cloud computing were reaching a tipping point where we could monitor the biome in entirely new ways, at entirely new scales,” Ethan Jackson, the senior director of Premonition, said in a video the company released today. “It was really the 2014 Ebola outbreak that led to this realization. How did one of the rarest viruses on the planet jump from animal to people to cause this outbreak? What signals are we missing that might have allowed us to predict it?”
Two years later, in 2016, when Zika emerged, the team had already built a small fleet of smart robotic traps that could autonomously identify and capture mosquito. The system identifies the mosquito and can then make a split-second decision whether to capture it or let it fly. In a single night, Jackson said, the trap has already been able to identify up to 10,000 mosquitos.
In the U.S., the first place where Microsoft deployed these systems was Harris County, Texas.
“Everything we do now in terms of mosquito treatment is reactive – we see a lot of mosquitoes, we go spray a lot of mosquitoes,” said Douglas E. Norris, an entomologist and Johns Hopkins University professor of molecular microbiology and immunology, who was part of this project. “Imagine if you had a forecasting system that shows, in a few days you’re going to have a lot of mosquitoes based on all this data and these models – then you could go out and treat them earlier before they’re biting, spray, hit them early so you don’t get those big mosquito blooms which then might result in disease transmission.”
This is, by all means, a very ambitious project. Why is Microsoft announcing it now, at its Ignite conference? Unsurprisingly, the whole system relies on the Microsoft Azure cloud to provide the storage and compute power to run — and it’s a nice way for Microsoft to show off its AI systems, too.
The president selectively highlighted statistics, falsely claimed New York and New Jersey were solely responsible for high national death rates and again wrongly asserted that a rise in cases was because of testing.
Hospitals are increasingly soliciting donations from patients, and the patients don’t much like it, a new survey finds.
Even the states hardest hit by the coronavirus have begun to allow more economic activity. What does that mean for playing the sports we love?
Contrary to Trump’s recent comments, specialists say, recent increases are real, and the virus is like a “forest fire” that will burn as long as there is fuel.
The technology was old, the data poor, the bureaucracy slow, the guidance confusing, the administration not in agreement. The coronavirus shook the world’s premier health agency, creating a loss of confidence and hampering the U.S. response to the crisis.
The president has served up a series of false and misleading statements as he seeks to counter uncomfortable facts about the spread of Covid-19 and questions about his push to reopen the economy.
There are no cases here, Kim Jong-un’s government claims, while acting as if its survival were at stake.
Thermal imaging wearables used in China to detect COVID-19 symptoms could soon be deployed in the U.S.
Per info Guan provided, Rokid’s T1 thermal glasses use an infrared sensor to detect the temperatures of up to 200 people within two minutes from up to three meters away. The devices carry a Qualcomm CPU, 12 megapixel camera and offer augmented reality features — for hands free voice controls — to record live photos and videos.
The Chinese startup (with a San Francisco office) plans B2B sales of its wearable devices in the U.S. to assist businesses, hospitals and law enforcement with COVID-19 detection, according to Guan.
Rokid is also offering IoT and software solutions for facial recognition and data management, as part of its T1 packages.
The company is working on deals with U.S. hospitals and local municipalities to deliver shipments of the smart glasses, but could not disclose names due to confidentiality agreements.
One commercial venture that could use the thermal imaging wearables is California based e-commerce company Weee!.
The online grocer is evaluating Rokid’s T1 glasses to monitor temperatures of its warehouse employees throughout the day, Weee! founder Larry Liu confirmed to TechCrunch via email.
On procedures to manage those who exhibit COVID-19 related symptoms, that’s something for end-users to determine, according to Rokid. “The clients can do the follow-up action, such as giving them a mask or asking to work from home,” Guan said.
The T1 glasses connect via USB and can be set up for IoT capabilities for commercial clients to sync to their own platforms. The product could capture the attention of U.S. regulators, which have become increasingly wary of Chinese tech firms’ handling of American citizen data. Rokid says it doesn’t collect info from the T1 glasses directly.
“Regarding this module…we do not take any data to the cloud. For customers, privacy is very important to them. The data measurement is stored locally,” according to Guan.
Founded in 2014 by Eric Wong and Mingming Zhu, Rokid raised $100 million at the Series B level in 2018. The business focuses primarily on developing AI and AR tech for applications from manufacturing to gaming, but developed the T1 glasses in response to China’s COVID-19 outbreak.
The goal was to provide businesses and authorities a thermal imaging detection tool that is wearable, compact, mobile and more effective than the common options.
Large scanning stations, such as those used in some airports, have drawbacks in not being easily portable and handheld devices — with infrared thermometers — pose risks.
“You have to point them to people’s foreheads…you need to be really close, it’s not wearable and you’re not practicing social distancing to use those,” Guang said.
Rokid pivoted to create the T1 glasses shortly after COVID-19 broke out in China in late 2019. Other Chinese tech startups that have joined the virus-fighting mission include face recognition giant SenseTime — which has installed thermal imaging systems at railway stations across China — and its close rival Megvii, which has set up similar thermal solutions in supermarkets.
On Rokid’s motivations, “At the time we thought something like this can really help the frontline people still working,” Guang said.
The startup’s engineering team developed the T1 product in just under two months. In China, Rokid’s smart glasses have been used by national parks staff, in schools and by national authorities to screen for COVID-19 symptoms.
Temperature detectors have their limitation, however, as research has shown that more than half of China’s COVID-19 patients did not have a fever when admitted to hospital.
The growth rate of China’s coronavirus cases — which peaked to 83,306 and led to 3,345 deaths — has declined and parts of the country have begun to reopen from lockdown. There is still debate, however, about the veracity of data coming out of China on COVID-19. That led to a row between the White House and World Health Organization, which ultimately saw President Trump halt U.S. contributions to the global body this week.
As COVID-19 cases and related deaths continue to rise in the U.S., technological innovation will become central to the health response and finding some new normal for personal mobility and economic activity. That will certainly bring fresh facets to the common tech conundrums — namely measuring efficacy and balancing benefits with personal privacy.
For its part, Rokid already has new features for its T1 thermal smart glasses in the works. The Chinese startup plans to upgrade the device to take multiple temperature readings simultaneously for up to four people at a time.
“That’s not on the market yet, but we will release this very soon as an update,” said Rokid’s U.S. Director Liang Guan .
In interviews across major television networks on Sunday, U.S. officials all but admitted that efforts to contain the spread of the novel coronavirus, COVID-19, have failed and that the country now needs to move to mitigate the effects of the continuing spread of the disease on the nation’s health and economy.
“We now are seeing community spread and we’re trying to help people understand how to mitigate the impact of disease spread,” U.S. Surgeon General Dr. Jerome Adams said on CBS’ Face the Nation on Sunday.
Dr. Adams’ concerns were echoed by Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
“There comes a time,” Fauci said in an interview on NBC’s Meet the Press, “when you have containment which [sic] you’re trying to find out who’s infected and put them in isolation. And if and when that happens — and I hope it’s if and not when — that you get so many people who are infected that the best thing you need to do is what we call mitigation in addition to containment.”
The admissions are supported by data from Johns Hopkins University, which indicates that despite government efforts to contain the novel coronavirus from spreading in the U.S. there are now at least 474 people infected with the virus across at least 31 states.
Exact information is difficult to ascertain since the Centers for Disease Control and Prevention said earlier this week that it would no longer be able to provide an official tally of tests conducted or under investigation. The CDC made the decision because states and private institutions are now authorized to conduct their own tests — making it difficult for the agency to keep up with the latest information.
“We are no longer reporting the number of PUIs or patients under investigation nor those who have tested negative,” said Dr. Nancy Messonnier, the director of the Center for the National Center for Immunization and Respiratory Diseases, at the CDC. “With more and more testing done at states, these numbers would not be representative of the testing being done nationally. States are reporting results quickly and even — states are reporting results quickly and in the event of a discrepancy between CDC and state case counts, the state case counts should always be considered more up to date.”
Mistakes were made
Faulty test kits and internal divisions over how to respond to the spread of the virus in the United States hamstrung early efforts to get an accurate picture of how rapidly the virus was moving through the population, according to multiple reports.
“They’ve simply lost time they can’t make up. You can’t get back six weeks of blindness,” Jeremy Konyndyk, a senior policy fellow at the Center for Global Development and an Obama-era administration staffer involved in the government’s response to the spread of the ebola virus, told The Washington Post. “To the extent that there’s someone to blame here, the blame is on poor, chaotic management from the White House and failure to acknowledge the big picture.”
There is a world in which a coordinated U.S. response to the outbreak of the coronavirus, which the Chinese government first reported to the World Health Organization in late December, would have been led by the global health security team within the National Security Council, but that group was dissolved in 2018 by the National Security Advisor at the time, John Bolton.
In that world, perhaps the U.S. could have ramped up the production and acquisition of testing kits, provisioned facilities in communities deemed to be more at risk with the necessary equipment, and issued emergency authorizations to enable public institutions to administer tests without undergoing formal approval processes. In that world, the CDC would not have needed to impose severe restrictions on who could be tested for the virus, because they would not have needed to limit the number of tests they could conduct to only the most pressing — or obvious — cases.
Instead, as reporting in both The Washington Post and the New York Times indicates, a series of poor decisions, slow responses, and technological missteps limited the government’s ability to respond effectively to the threat.
The problems seem to have been threefold — the Centers for Disease Control did not move quickly enough to manufacture test kits at scale (either because of lack of funding or political will) nor did it open up testing options to other institutions that could have worked to develop tests — and because of the limited availability of tests, the CDC rationed how many tests were performed. Those issues were compounded by the initial release of faulty tests by the CDC in early February.
As former U.S. Food and Drug Administration official Scott Gottlieb wrote on Twitter in early February, “Since CDC and FDA haven’t authorized public health or hospital labs to run the tests, right now #CDC is the only place that can. So, screening has to be rationed. Our ability to detect secondary spread among people not directly tied to China travel is greatly limited.”
There are many reasons to have testing kits run through the CDC and state labs affiliated with the center. Chiefly, tests developed and distributed by the CDC can be conducted free-of-charge at public health labs, while corporate labs and private healthcare facilities can charge for the tests they develop.
(There has already been one story involving a man from Florida who was stuck with a $3000 bill for his decision to be pre-emptively tested for the coronavirus after returning from a trip to China.)
However, the inability of the CDC and federal public health officials to respond quickly enough was soon apparent throughout February.
A system for tracking travelers who were returning from China went down just as federal officials were directing state agencies to track their movements, according to a report in The New York Times. Meanwhile, the head of the Department of Health and Human Services, Alex Azar, was estimating that the U.S. needed at least 300 million respirator masks for healthcare workers — the national emergency stockpile only had 12 million on hand, and many of those were expired, according to the Times.
Meanwhile, the CDC’s coronavirus test had a flawed component that led to inaccurate tests, which limited the testing efforts even further. And the limitations imposed on who could receive the tests have meant that there is still no accurate picture of how widely the disease has spread.
As recently as Friday, a nurse at a hospital in California was being denied access to the coronavirus test.
“I am currently sick, in quarantine, after caring for a patient who tested positive. I am awaiting permission from the federal government to allow for my testing even after my physician and county health professional ordered the test,” the nurse said in an issued statement. “The national CDC would not initiate the test. They said they would not test me, because if I was wearing the recommended protective equipment, then I wouldn’t have the coronavirus… Later they called back and now it’s an issue with something called the identifier number. They claim they prioritize running samples by illness severity and that there are only so many to give out each day. So I have to wait in line for the results. This is not a ticket dispenser at a deli counter, it’s a public health emergency…. I’m appalled at the level of bureaucracy that’s preventing nurses from getting tested. Delaying this test puts the whole community at risk.”
“When the CDC test was delayed, then the cases started appearing outside of China, there should have been a quicker response to get diagnostic testing going,” Melissa Miller, a director of the clinical molecular microbiology laboratory at the University of North Carolina at Chapel Hill School of Medicine, told the Washington Post.
‘We have an epidemic underway here in the United States’
The Federal Government is now facing an epidemic, according to health experts, and the question now is how can it help states and local governments respond.
“We have an epidemic underway here in the United States,” said former Food and Drug Administration commissioner, Scott Gottlieb, in an interview on Face the Nation.
Gottlieb, who recently returned to his position as a managing partner at the venture capital firm NEA, has been monitoring the government’s response from afar and was once rumored to be a candidate for the position of “Coronavirus Czar” overseeing the Administration’s response to the outbreak.
“We have to implement broad mitigation strategies. The next two weeks are really going to change the complexion in this country. We’ll get through this, but it’s going to be a hard period. We’re looking at two months probably of difficulty,” said Gottlieb. “To give you a basis of comparison, two weeks ago, Italy had nine cases. Ninety-five percent of all their cases have been diagnosed in the last 10 days. For South Korea, 85 percent of all their cases have been diagnosed in the last 10 days. We’re entering that period right now of rapid acceleration. And the sooner we can implement tough mitigation steps in places we have outbreaks like Seattle, the- the lower the scope of the epidemic here.”
Part of mitigation involves continuing to track the spread of the disease, and Gottlieb has been encouraging the FDA to move quickly to get new tests approved for weeks. Already, the Gates Foundation and private companies are rushing to bring an at-home coronavirus test kit to market — and ways to share the results from testing with appropriate government agencies.
But testing alone isn’t enough, says Gottlieb. The U.S. needs to “[close] businesses, close large gatherings, close theaters, cancel events,” Gottlieb said.
Businesses have started to cancel large conferences and events, and universities like Stanford are turning to remote classes for the remainder of their winter term. No city or state has yet to take measures as drastic as Italy, which closed down the entire Northern region of the country over the weekend in an effort to contain the spread of the coronavirus.
“I think we need to think about how do we provide assistance to the people of these cities who are going to be hit by hardship, as well as the localities themselves to try to give them an incentive to do this.”
His recommendations align with policy suggestions issued recently by the International Monetary Fund, which are all steps that the U.S. government could take should it choose to proactively approach its response to the virus’ spread.
Indeed, the over $8 billion coronavirus response package approved by Congress last week goes a long way to addressing the first suggestion from the IMF, which is to spend on the prevention, detection, control, treatment and containment of the virus.
Equally as important, according to the IMF, is to provide cash flow relief to the people and firms that are most affected — either in the form of wage subsidies, accelerated and expanded unemployment benefits, or tax benefits for companies affected by the virus outbreak.
“We’re going to end up with a very big federal bailout package here for stricken businesses, individuals, cities and states,” said Gottlieb. “We’re better off doing it upfront and giving assistance to get them to do the right things than do it on the back end after we’ve had a very big epidemic.”
Meanwhile, leadership in the U.S. at the highest level insists that there’s nothing to worry about.